194 related articles for article (PubMed ID: 18653231)
1. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
Spänkuch B; Steinhauser I; Wartlick H; Kurunci-Csacsko E; Strebhardt KI; Langer K
Neoplasia; 2008 Mar; 10(3):223-34. PubMed ID: 18320067
[TBL] [Abstract][Full Text] [Related]
3. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
Steinhauser I; Langer K; Strebhardt K; Spänkuch B
J Drug Target; 2009 Sep; 17(8):627-37. PubMed ID: 19591537
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
6. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
Steinhauser I; Spänkuch B; Strebhardt K; Langer K
Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
9. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
10. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.
Wagner S; Rothweiler F; Anhorn MG; Sauer D; Riemann I; Weiss EC; Katsen-Globa A; Michaelis M; Cinatl J; Schwartz D; Kreuter J; von Briesen H; Langer K
Biomaterials; 2010 Mar; 31(8):2388-98. PubMed ID: 20031203
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation.
Kufleitner J; Worek F; Kreuter J
J Microencapsul; 2010; 27(7):594-601. PubMed ID: 20923399
[TBL] [Abstract][Full Text] [Related]
12. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
14. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
Weyermann J; Lochmann D; Georgens C; Zimmer A
Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
[TBL] [Abstract][Full Text] [Related]
15. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
[TBL] [Abstract][Full Text] [Related]
16. Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting.
Gong G; Zhi F; Wang K; Tang X; Yuan A; Zhao L; Ding D; Hu Y
Nanotechnology; 2011 Jul; 22(29):295603. PubMed ID: 21673386
[TBL] [Abstract][Full Text] [Related]
17. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
Wang J; Tao X; Zhang Y; Wei D; Ren Y
Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
[TBL] [Abstract][Full Text] [Related]
18. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
